Salinomycin, an inhibitor of LRP5/6, inhibits the growth of GC by inhibiting Wnt signaling in CSCs, and salinomycin targeting Wnt/β-catenin pathway may have important clinical therapeutic value in gastric cancer (69). Here, LRP5 is linked to gastric cancer.